// App-Quantinova.ai

: Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Genotype Is Beneficial to Septic Shock Outcome While HMG-CoA Reductase Loss-of-Function Genotype Is Not

Researchers

Presenter

  • H. Kong

Principal Investigators

  • J. H. Boyd

  • J. A. Russell

  • K. R. Walley

Medical Centers

  • Centre for Heart Lung Innovation, St. Pauls Hospital/University of British Columbia, Vancouver, BC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • Proprotein convertase subtilisin/kexin type 9

Drug/Treatment

  • vasopressin Injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Canadian Institutes of Health Research (CIHR)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved